BRIEF published on 07/09/2024 at 08:15, 4 months 12 days ago Andera Partners Co-Leads €63 Million Series A for Biotech SciRhom Series A Financing Biopharmaceuticals Andera Partners Autoimmune Disorders SciRhom
PRESS RELEASE published on 07/09/2024 at 08:10, 4 months 12 days ago Andera Partners co-leads a €63 million Series A round for Munich-based autoimmune biotech SciRhom Andera Partners co-leads a €63 million Series A round for Munich-based autoimmune biotech SciRhom to advance novel iRhom2 antibody therapy towards clinical proof-of-concept Andera Partners SciRhom Autoimmune Biotech Series A Round IRhom2 Antibody
BRIEF published on 03/14/2024 at 11:15, 8 months 7 days ago Andera Partners’ Portfolio Company Tubulis Secures €128 Million in Series B2 Financing Clinical Trials Andera Partners Tubulis Series B2 Financing ADC Development
PRESS RELEASE published on 03/14/2024 at 11:10, 8 months 7 days ago Andera Partners’ portfolio company Tubulis closes upsized €128 Million Series B2 to accelerate the development of its ADC Pipeline Andera Partners’ portfolio company Tubulis closes upsized €128 Million Series B2 financing to accelerate ADC pipeline development Andera Partners Tubulis €128 Million Series B2 ADC Pipeline Biotech Financing
BRIEF published on 03/14/2024 at 09:05, 8 months 7 days ago AstraZeneca Acquires Amolyt Pharma for up to $1.05 Billion Acquisition Biopharmaceutical AstraZeneca Amolyt Pharma Rare Diseases
PRESS RELEASE published on 03/14/2024 at 09:00, 8 months 7 days ago Amolyt Pharma, an Andera Partners’ portfolio company, announces its sale to AstraZeneca Amolyt Pharma, a clinical-stage biopharmaceutical company specializing in therapeutic peptides, is being acquired by AstraZeneca for $1.05 billion. The transaction is expected to close in Q3 2024 Acquisition AstraZeneca Amolyt Pharma Therapeutic Peptides Rare Endocrine Diseases
PRESS RELEASE published on 05/15/2023 at 09:00, 1 year 6 months ago Andera Partners co-leads a €40 million Series A of Dualyx, a Belgian biotech developing novel Treg therapies for autoimmune diseases
PRESS RELEASE published on 05/10/2023 at 09:00, 1 year 6 months ago Andera Partners appoints Stefan Keitel Senior Advisor DACH region further strengthening its presence in the German, Austrian and Swiss private equity markets
PRESS RELEASE published on 04/18/2023 at 09:15, 1 year 7 months ago Andera Partners co-leads a Series A extension round totalling € 47.75 million for radiopharmaceutical company Ariceum Therapeutics
PRESS RELEASE published on 04/13/2023 at 12:45, 1 year 7 months ago Andera Partners leads $48.5 Million Series A financing for medical device company BioVentrix®
Published on 11/21/2024 at 14:00, 14 minutes ago Demotech, Inc. Assigns a Financial Stability Rating(R) of A, Exceptional, to Steadily Insurance Company
Published on 11/21/2024 at 14:00, 14 minutes ago Montara Raises $5.4M to Help Organizations Deliver Better Data Products Faster
Published on 11/21/2024 at 14:00, 14 minutes ago Tevir Capital LP Ltd. Updates Early Warning Reporting in Respect of VerticalScope Holdings Inc.
Published on 11/21/2024 at 13:30, 44 minutes ago AirIQ Announces September 30, 2024 Quarterly Results Company Reports Double-Digit Growth in Recurring Revenue
Published on 11/21/2024 at 12:35, 1 hour 38 minutes ago audius with successful third quarter 2024 - total revenue grows by +9.2% and EBITDA by +14.6
Published on 11/21/2024 at 12:15, 1 hour 59 minutes ago Hardman & Co Investor Forum Research on Shield Therapeutics (STX): Proactive cash management to cashflow-breakeven
Published on 11/21/2024 at 06:58, 7 hours 16 minutes ago Net Asset Value per share increases with 9.4% in six months to EUR 55.6 thanks to continued strong growth performance of the portfolio
Published on 11/20/2024 at 19:20, 18 hours 54 minutes ago Peugeot Invest Board of Directors to evolve following the May 2025 Annual General Meeting
Published on 11/20/2024 at 17:45, 20 hours 29 minutes ago MEDESIS PHARMA HAS COMPLETED ITS CLINICAL STUDY FOR THE TREATMENT OF ALZHEIMER'S DISEASE WITH NANOLITHIUM
Published on 11/20/2024 at 17:45, 20 hours 29 minutes ago Disclosure of Share Capital and Voting Rights Outstanding as of October 31, 2024
Published on 11/20/2024 at 07:45, 1 day 6 hours ago Gimv sells to Fremman Capital a majority stake in outpatient rehabilitation specialist rehaneo
